Drug Profile
Sozinibercept - Opthea
Alternative Names: OPT-302; soluble VEGFR-3; VGX 300Latest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Vegenics
- Developer Opthea
- Class Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor C inhibitors; Vascular endothelial growth factor D inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Wet age-related macular degeneration
- Phase I/II Diabetic macular oedema
Most Recent Events
- 14 Feb 2024 Opthea completes enrolment in the phase III COAST trial for Wet age-related macular degeneration (Combination therapy, Treatment-naïve) in US, Argentina, Australia, Austria, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, South Korea, Latvia, Lithuania, Netherlands, Philippines, Poland, Puerto Rico, Slovakia, Spain, Taiwan, the UK and Bulgaria (IV) (NCT04757636)
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 28 Oct 2022 9371581 - No updates